FDA Expands Enhertu Approval to HER2-Ultralow Breast Cancer

[ad_1]

(MedPage Today) — The FDA expanded the approval of trastuzumab deruxtecan (T-DXd, Enhertu) to include treatment of unresectable/metastatic hormone receptor (HR)-positive, HER2-low/ultralow breast cancer.
Approval stipulates use in patients with…

[ad_2]

Source link : https://www.medpagetoday.com/hematologyoncology/breastcancer/113982

Author :

Publish date : 2025-01-28 20:41:44

Copyright for syndicated content belongs to the linked Source.